<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13100">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936375</url>
  </required_header>
  <id_info>
    <org_study_id>[2016]128k</org_study_id>
    <nct_id>NCT02936375</nct_id>
  </id_info>
  <brief_title>Iguratimod as Treatment for Active Lupus Nephritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <brief_summary>
    <textblock>
      This study is a 52-week, randomized, open, active-controlled trial of patients with active
      diffused lupus nephritis, to assess the efficacy and safety of a novel chemical synthetic
      agent iguratimod. The subjects will randomly receive iguratimod or cyclophosphamide followed
      with azathioprine, both combined with steroids.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2017</start_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal remission rate</measure>
    <time_frame>Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal remission rate</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal flare rate</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>Week 52</time_frame>
    <description>adverse events are assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SLEDAI-2K score</measure>
    <time_frame>Week 52</time_frame>
    <description>SLE SLE disease activity index (2000)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BILAG score</measure>
    <time_frame>Week 52</time_frame>
    <description>British Isles lupus assessment group score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PGA</measure>
    <time_frame>Week</time_frame>
    <description>Patient general assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lupus Nephritis</condition>
  <arm_group>
    <arm_group_label>Iguratimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iguratimod 25mg twice a day, oral administrated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyc+AZA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous cyclophosphamide (1g/m2) every 4 weeks for six times, followed with oral azathioprine (2mg/kg/d).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iguratimod</intervention_name>
    <arm_group_label>Iguratimod</arm_group_label>
    <other_name>T-614</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Cyc+AZA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azathioprine</intervention_name>
    <arm_group_label>Cyc+AZA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active lupus nephritis:

               -  Fulfill ACR classification criteria (2009) for SLE

               -  Proteinuria ≥1g/24h at screening

               -  Nephritis of class III, IV, V, III+IV or IV+V, confirmed by renal pathology
                  within 90 days prior to screening

          -  Body weight ≥40kg

          -  SLE-2K score ≥8

          -  Agreement of contraception

          -  Informed consent obtained

        Exclusion Criteria:

          -  Active severe SLE-driven renal disease or unstable renal disease at screening

          -  Active severe or unstable neuropsychiatric SLE

          -  Clinically significant active infection including ongoing and chronic infections

          -  History of receiving cyclophosphamide, azathioprine, tacrolimus , mycophenolate
             moetil or rituximab treatment with 90 days prior to screening

          -  History of human immunodeficiency virus (HIV)

          -  Confirmed Positive tests for hepatitis B or positive test for hepatitis C

          -  Active tuberculosis

          -  Live or attenuated vaccine within 4 weeks prior to screening

          -  Subjects with significant hematologic abnormalities

          -  Abnormal liver function test at screening (ALT, AST or total bilirubin over 2 fold of
             upper normal level

          -  History of peptic ulcer or GI bleeding; treatment with warfarin or other
             anticoagulants within last 14 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chunde Bao, M.D.</last_name>
    <phone>86-21-63284622</phone>
    <email>baochunde_1678@126.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 26, 2016</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lupus</keyword>
  <keyword>nephritis</keyword>
  <keyword>iguratimod</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
